Combination of Trastuzumab and Triple FLOT Chemotherapy (5-Fluorouracil/Leucovorin, Oxaliplatin, and Docetaxel) in Patients with HER2-Positive Metastatic Gastric Cancer: Report of 3 Cases-Reference-Cited by-同舟云学术

Combination of Trastuzumab and Triple FLOT Chemotherapy (5-Fluorouracil/Leucovorin, Oxaliplatin, and Docetaxel) in Patients with HER2-Positive Metastatic Gastric Cancer: Report of 3 Cases

Published:2012 Issue:9 Volume:35 Page:505-508
ISSN:1423-0240
Container-title:Onkologie
language:en
Short-container-title:Onkologie

Author:

Al-Batran Salah-Eddin,Hozaeel Wael,Jäger Elke

Publisher

S. Karger AG

Subject

Cancer Research,Oncology,Hematology,General Medicine

Reference7 articles.

1. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

2. Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group

3. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie

4. S3-Leitlinie „Magenkarzinom” -

5. Is there any advantage to combined trastuzumab and chemotherapy in perioperative setting her 2neu positive localized gastric adenocarcinoma?

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in translational therapy for locally advanced gastric cancer;World Journal of Clinical Cases;2023-04-16

2. Interest of the Addition of Taxanes to Standard Treatment in First-Line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients;Frontiers in Oncology;2022-03-07

3. Cure Is Possible: Extensively Metastatic HER2-Positive Gastric Carcinoma with 5 years of Complete Remission after Therapy with the FLOT Regimen and Trastuzumab;Case Reports in Gastroenterology;2022-02-17

4. Hyperactivation of HER2-SHCBP1-PLK1 axis promotes tumor cell mitosis and impairs trastuzumab sensitivity to gastric cancer;Nature Communications;2021-05-14

5. Response to Zhong-Qing et al Regarding “GI Cancers Lymph Node Status Significance After Neoadujuvant Chemotherapy: An Unsolved Problem”;Annals of Surgery;2021-01-07